• CT:VQ approved by TGA and included in ARTG
• Australia joins other markets with regulatory clearance
• CT:VQ is a non-contrast ventilation-perfusion solution
• Australia's high CT scanner density supports rapid deployment
• CT:VQ aims to become the new standard for functional lung assessment

4DMedical Limited (ASX:4DX) announced that its non-contrast ventilation-perfusion imaging solution, CT:VQ, has been approved by the Therapeutic Goods Administration (TGA) and included in the Australian Register of Therapeutic Goods (ARTG), enabling commercial deployment across Australia. CT:VQ is a software-only, non-contrast, ventilation-perfusion solution that enables functional lung imaging using existing CT infrastructure. Australia's high CT scanner density supports rapid nationwide deployment. CT:VQ aims to become the new standard for functional lung assessment globally. With TGA approval secured, 4DMedical will prepare an application to the Medical Services Advisory Committee (MSAC) to pursue Medicare Benefits Schedule (MBS) reimbursement for CT:VQ.

4DMedical aims to leverage CT:VQ's regulatory approvals to establish it as the new standard for functional lung assessment globally.